"Febrile Neutropenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fever accompanied by a significant reduction in the number of NEUTROPHILS.
- Febrile Neutropenia
- Febrile Neutropenias
- Neutropenia, Febrile
- Neutropenias, Febrile
Below are MeSH descriptors whose meaning is more general than "Febrile Neutropenia".
Below are MeSH descriptors whose meaning is more specific than "Febrile Neutropenia".
This graph shows the total number of publications written about "Febrile Neutropenia" by people in this website by year, and whether "Febrile Neutropenia" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Febrile Neutropenia" by people in Profiles.
A prediction model for bacteremia and transfer to intensive care in pediatric and adolescent cancer patients with febrile neutropenia. Sci Rep. 2022 05 06; 12(1):7429.
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539.
Pediatric Invasive Fungal Risk Score in Cancer and Hematopoietic Stem Cell Transplantation Patients With Febrile Neutropenia. J Pediatr Hematol Oncol. 2022 Mar 01; 44(2):e334-e342.
Febrile Neutropenia Syndromes in Children: Risk Factors and Outcomes of Primary, Prolonged, and Recurrent Fever. J Pediatr Hematol Oncol. 2021 Oct 01; 43(7):e962-e971.
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021 02 01; 96(2):208-217.
Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity. Anticancer Res. 2018 Jun; 38(6):3543-3549.
Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Pract. 2019 Jul; 25(5):1112-1118.
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.
Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia. J Oncol Pharm Pract. 2017 Dec; 23(8):575-581.
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. Br J Haematol. 2014 Dec; 167(5):699-702.